Business context and reporting period
Important entity mismatch: The supplied filing is Dynamics Special Purpose Corp.’s Form 10-Q, not a filing identified as Senti Biosciences Holdings, Inc. It covers the quarter ended June 30, 2021 and results from inception on March 1, 2021 through June 30, 2021.
Dynamics was a newly formed SPAC with no operating business or revenue. It completed its IPO on May 28, 2021 and was searching for a business combination; no target is identified in the filing.
Financial results and condition
- Revenue: No operating revenue. The company reported $965 of trust-account interest and dividend income for the quarter and inception-to-date period.
- Loss: Net loss was $206,066 for the second quarter and $207,244 from inception through June 30. Quarterly expenses included $152,866 of operating and formation costs and $54,165 of franchise tax expense.
- Cash flow: Inception-to-date cash used in operations was $934,675; cash used in investing was $230.0 million, primarily deposited into the trust; financing provided $232.0 million. Ending cash outside the trust was $1,096,895.
- Assets and liquidity: Total assets were $231.9 million, including $230.0 million in the trust account. Working capital was $1,823,361. Management believed available working capital and borrowing capacity would meet needs through the earlier of a business combination or one year from the filing.
- Debt and obligations: No outstanding promissory-note balance was reported; a $250,000 sponsor loan was repaid in May. The balance sheet included an $8.05 million deferred underwriting fee, payable only if a business combination is completed. No off-balance-sheet arrangements were reported.
- Equity and redemptions: $218.8 million representing 21,877,432 redeemable Class A shares was classified as temporary equity. Stockholders’ equity was $5.0 million.
Changes versus the prior comparable period
The company was incorporated in March 2021, so there is no prior-year comparable period. The quarter’s $206,066 net loss accounted for nearly all of the $207,244 inception-to-date loss. The IPO and private placement were completed during the quarter, and $230.0 million was placed in the trust account.
Outlook, risks, and other notable items
- The company had until May 28, 2023 to complete a business combination. If unsuccessful, it was required to cease operations and redeem public shares, subject to applicable requirements.
- A business combination required a target or targets with aggregate fair market value of at least 80% of the trust account, subject to stated exclusions, and the post-transaction company had to acquire control. Public shareholders generally could redeem shares in connection with a transaction.
- Management cautioned that COVID-19 could adversely affect the company’s financial position, operations, or target search, but said the impact was not readily determinable.
- The sponsor could, but was not obligated to, provide working-capital loans; up to $2.0 million could be convertible into shares at the lender’s option. Terms were not established and no written agreements existed.
- Management reported disclosure controls were effective as of June 30, 2021, with no material change in internal control during the quarter. The filing reported no legal proceedings and no material changes to prospectus risk factors.
Important facts for investors to verify
- Confirm the filing belongs to Dynamics Special Purpose Corp. and not Senti Biosciences Holdings, Inc.
- Check for subsequent filings identifying a business-combination target, transaction terms, and redemption or financing developments.
- Verify current trust-account assets, cash available outside the trust, and any sponsor working-capital loans.
- Review the business-combination deadline, deferred underwriting fee, redemption terms, and risks disclosed in the IPO prospectus.